Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely however we are beginning to have limited access to the office from 6th July 2020. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Advanced
Trials portfolio
ALLCAR19
Immunotherapy for high risk/relapsed CD19+ Acute Lymphoblastic Leukaemia using CAR T-cells to target CD19
ALLCAR19 is a multi-site, non-randomised phase I trial in adults with high risk or refractory CD19+ B-cell Acute Lymphoblastic Leukaemia. The Advanced Therapy Investigational Medicinal Product (ATIMP) [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
CARD
CAR19 Donor Lymphocytes for relapsed CD19+ malignancies following allogeneic transplantation
CARD is a single centre, single arm intra-patient dose-escalation phase I study in adults with relapsed CD19+ malignancies following allogeneic stem cell transplantation. The Advanced Therapies Invest [...]
Area: Advanced therapies
Phase: Phase I
Status: In follow-up (non-recruiting)
CARPALL
Immunotherapy with CD19 CAR redirected T-cells for high risk/relapsed paediatric CD19+ acute lymphoblastic leukaemia and other haematological malignancies
A multi-centre, non-randomised, open label phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults with high risk, relapsed CD19+ haematolo [...]
Area: Advanced therapies
Phase: Phase I
Status: Recruitment suspended
CD-19TPALL
Immunotherapy with CD19? gene modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia
a multi-site, non-randomised, phase I/II, paediatric trial with 2 arms. The Advanced Therapy Medicinal product (ATMP) tested in the study is donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) tran [...]
Area: Advanced therapies
Phase: Phase I/II
Status: Archived
COBALT
Evaluation of CAR19 T-cells as an optimal bridge to allogeneic transplantation.
Single centre, single arm dose-escalation phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults with resistant or relapsed DLBCL. The ATIMP tested in this s [...]
Area: Advanced therapies
Phase: Phase I
Status: In follow-up (non-recruiting)
ICAT
Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant.
ICAT is a multi-centre randomised phase II trial in adult patients with an underlying haematological malignancy undergoing unrelated donor peripheral blood stem cell transplant with Alemtuzumab-based [...]
Area: Advanced therapies
Phase: Phase II
Status: Closed
ITREC
Immunotherapy with Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease after Solid Organ Transplant
ITREC is a multi-site, non-randomised phase I trial in children and adults with Post Transplant Lymphoproliferative Disease (PTLD) after solid organ transplant. The Advanced Therapy Investigational Me [...]
Area: Advanced therapies
Phase: Phase I
Status: Active (recruiting)
TACTICAL
Targeted stromal cells expressing TRAIL as a therapy for lung cancer
Phase I:Single site dose de-escalation design with a modified Bayesian continual reassessment method (mCRM) to estimate the recommended Phase II dose (RP2D) of MSCTRAIL in combination with pemetrexed/ [...]
Area: Advanced therapies
Phase: Phase I/II
Status: Active (recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2020 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us